Patents by Inventor Chunte Peng

Chunte Peng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ultrabright lanthanide-doped nanoparticles
    Patent number: 11603492
    Abstract: An upconversion single molecule probe is provided that includes a core having a nanoparticle seed crystal, where the nanoparticle seed crystal is an upconversion seed crystal, a first shell enveloping the core, and a second shell enveloping the first shell.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: March 14, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Steven Chu, Qian Liu, Yunxiang Zhang, Chunte Peng
  • Ultrabright Lanthanide-Doped Nanoparticles
    Publication number: 20220041926
    Abstract: An upconversion single molecule probe is provided that includes a core having a nanoparticle seed crystal, where the nanoparticle seed crystal is an upconversion seed crystal, a first shell enveloping the core, and a second shell enveloping the first shell.
    Type: Application
    Filed: May 9, 2019
    Publication date: February 10, 2022
    Inventors: Steven Chu, Qian Liu, Yunxiang Zhang, Chunte Peng
  • MUTAGENIC NUCLEOSIDE ANALOGS AND USES THEREOF
    Publication number: 20170313736
    Abstract: The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pKa (e.g., to a pKa between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits.
    Type: Application
    Filed: July 6, 2017
    Publication date: November 2, 2017
    Applicant: Massachusetts Institute of Technology
    Inventors: John M. Essigmann, Andrei Tokmakoff, Bogdan I. Fedeles, Vipender Singh, Chunte Peng
  • Mutagenic nucleoside analogs and uses thereof
    Patent number: 9714265
    Abstract: The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pKa (e.g., to a pKa between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: July 25, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: John M. Essigmann, Andrei Tokmakoff, Bogdan I. Fedeles, Vipender Singh, Chunte Peng
  • MUTAGENIC NUCLEOSIDE ANALOGS AND USES THEREOF
    Publication number: 20160222050
    Abstract: The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pKa (e.g., to a pKa between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits.
    Type: Application
    Filed: January 28, 2016
    Publication date: August 4, 2016
    Inventors: John M. Essigmann, Andrei Tokmakoff, Bogdan I. Fedeles, Vipender Singh, Chunte Peng